Funding for Programs
Promiliad has been exceptionally successful in receiving highly competitive awards from the National Institutes of Health for our antibiotic development programs. To date we have been awarded multiple phase I and phase II SBIR/STTR awards, totaling over $6 million in non-dilutive funds.

The University Of Montana
2020 Single application
thixotropic antibiotic delivery
systems for Otitis externa

The University Of Montana
2019 Novel antibacterial
agents derived from
natural products

The University Of Montana
2018 Single application
thixotropic antibiotic delivery
systems for Otitis externa

The University Of Montana
2016 Novel antibacterial
agents derived from
natural products

–
2013 Development of stable
isosteres of dihydrofolate
reductase inhibitors as
antibacterial agents

The University of Connecticut
2010 Potent antifolates as
new therapeutics for MRSA

The Ohio State University
2009 The identification
of novel negative allosteric
modulators of the
nicotinic receptor

The University of Connecticut
2009 New antibiotics
targeting fatty acid
biosynthesis

Ohio University
2008 Isoindolinones as
antibacterial agents

Dartmouth College
2006 Natural feedstocks
for diversity-oriented
synthesis

Dartmouth College
2006 Potent and selective
DHFR inhibitors for
treating cryptosporidiosis

Ohio University
2005 Fermentation initiated
antibiotic syntheses

University of Florida
2004 Natural feedstocks
for diversity-oriented
synthesis